BenevolentAI appoints Dr Joerg Moeller as CEO
Betsy Goodfellow | January 25, 2024 | Appointment | Business Services | BenevolentAI, CEO, Dr Joerg Moeller, appointment
BenevolentAI has announced that it has appointed Dr Joerg Moeller MD PhD as chief executive officer and executive board member effective immediately.
Joerg Moeller brings with him years of experience, having led global research and development (R&D) organisations, and working within commercial and operational roles. He has previous experience in drug discovery collaborations with artificial intelligence (AI) companies.
Previously he has worked as executive vice president (EVP), head of global R&D and member of the Global Leadership Team at LEO Pharma A/S. prior to this he work ed at Bayer AG for over twenty years, holding various leadership roles, including EVP, head of Pharmaceuticals Research and Development and member of the Executive Committee of the pharmaceuticals division of Bayer.
Dr François Nader, chair of Benevolent AI, stated: “Along with the rest of the Board, I am delighted to welcome Joerg. Joerg is an outstanding leader with extensive experience across all stages of R&D. He is a strong advocate of AI as a driver of discovery innovation and effectiveness. With his track record of delivering growth through driving performance, I am confident that Joerg will leverage our proprietary and validated Benevolent Platform™ to deliver our patient-centric revenue generating strategy.”
Commenting on his appointment, Dr Joerg Moeller, added: “I am excited by the opportunity to lead BenevolentAI. I believe the Company is well-positioned to further capitalise on its Platform, pipeline and research capabilities in order to strengthen the Company’s market position and continue to build its commercial activities. I am passionate about fostering a culture of excellence, innovation, and diversity and I look forward to working with the Board, the Leadership Team and BenevolentAI employees to create value for all its stakeholders ultimately helping to deliver treatments to the patients who need them.”
Betsy Goodfellow
Related Content
David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
AstraZeneca adds new heart failure target through collaboration with BenevolentAI
BenevolentAI has announced that AstraZeneca has added a novel heart failure target to its discovery …
CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in …
